OneSource Specialty Pharma Limited has disclosed the creation of an encumbrance over 64,00,000 equity shares by Tenshi Pharmaceuticals Private Limited in favor of Catalyst Trusteeship Limited. The disclosure was made under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on January 07, 2026.

Pledge Details and Structure

The pledge was created as security for zero coupon, secured, unrated, unlisted, redeemable non-convertible debentures worth ₹1000,00,00,000 issued by Karuna Ventures Private Limited. Karuna Ventures is a group company of Tenshi Pharmaceuticals, which serves as the pledgor in this transaction.

Shareholding Pattern and Background

Tenshi Pharmaceuticals Private Limited holds 2,05,24,714 equity shares in OneSource Specialty Pharma Limited, constituting 17.92% of the company's issued and paid-up share capital. The total equity share capital of OneSource remains unchanged at 11,45,25,216 paid-up equity shares of ₹1 each before and after this encumbrance.

Progressive Pledge Creation

The current disclosure represents the second tranche of share pledging under the debenture arrangement. Previously, on December 16, 2025, Tenshi Pharmaceuticals had created a pledge over 20,00,000 equity shares constituting 1.75% of the issued share capital. The recent pledge of 44,00,000 additional shares on January 05, 2026, brings the total pledged shares to 64,00,000.

Regulatory Framework

The pledge was executed pursuant to a debenture trust deed and share pledge agreement both dated November 27, 2025. Under the takeover regulations, encumbrance over shares is treated as an acquisition, necessitating this disclosure. Catalyst Trusteeship Limited acts as the debenture trustee for the benefit of debenture holders, including their assigns, transferees, successors, and novatees.

Company Information

OneSource Specialty Pharma Limited is listed on both BSE Limited and National Stock Exchange of India Limited. The company's registered office is located at Cyber One, Unit No. 902, Sector 30A, Plot No. 4 & 6, Vashi, Navi Mumbai – 400703. Catalyst Trusteeship Limited, serving as the debenture trustee, does not belong to the promoter or promoter group of OneSource Specialty Pharma Limited.

Onesource Specialty Pharma Limited has disclosed that one of its promoter entities has pledged a significant portion of equity shares to meet business requirements. The pharmaceutical company made this announcement through a regulatory filing dated December 18, 2025.

Share Pledge Details

Tenshi Pharmaceuticals Private Limited pledged 20,00,000 equity shares of Onesource Specialty Pharma Limited on December 16, 2025. The pledge was executed to address certain business and operational needs of the promoter entity.

Regulatory Compliance

The disclosure was made in compliance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The company submitted the required Form to both the Bombay Stock Exchange and National Stock Exchange of India.

The filing was signed by Pudhuccode Radhakrishnan Kannan, Director of Tenshi Pharmaceuticals Private Limited, with DIN 03435209.

Company Information

Onesource Specialty Pharma Limited operates in the pharmaceuticals sector with its registered office located in Navi Mumbai, Maharashtra. The company's corporate office is situated in Bangalore, Karnataka.

Tenshi Pharmaceuticals Private Limited, the pledging entity, has its registered office in Bengaluru, Karnataka. The entity operates under CIN: U74999KA2016PTC200180.

This pledge transaction represents a corporate action undertaken by the promoter group to meet specific business requirements while maintaining regulatory compliance and transparency with market participants.